Cargando…
Practical Management of Patients with Atopic Dermatitis on Dupilumab
INTRODUCTION: Dupilumab is approved to treat moderate-to-severe atopic dermatitis (AD) in several countries in patients as young as 6 years of age. Since its approval, practical issues related to the use of dupilumab for AD have arisen, with particular interest in transitioning from current therapie...
Autores principales: | Papp, Kim A., Hong, Chih-ho, Lansang, M. Perla, Turchin, Irina, Adam, David N., Beecker, Jennifer R., Bissonnette, Robert, Gooderham, Melinda J., Jack, Carolyn, Joseph, Marissa, Lynde, Charles W., Shear, Neil H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435113/ https://www.ncbi.nlm.nih.gov/pubmed/34510403 http://dx.doi.org/10.1007/s13555-021-00586-w |
Ejemplares similares
-
Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis
por: Eshtiaghi, Panteha, et al.
Publicado: (2018) -
Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
por: Le, Michelle, et al.
Publicado: (2021) -
Dupilumab for atopic dermatitis
Publicado: (2019) -
Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis
por: Gooderham, Melinda J., et al.
Publicado: (2021) -
Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023)